Glycoprotein (GP) IIb/IIIa inhibitors v placebo or control for acute coronary syndromes not routinely scheduled for coronary revascularisation*
| Outcomes | GP IIb/IIIa inhibitors | Placebo or control | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| Death or MI at 5 days | 5.7% | 6.9% | 15% (7 to 22) | 97 (67 to 223) |
| Death or MI at 30 days | 11% | 12% | 8% (2 to 14) | 106 (63 to 479) |
| Death at 5 days | 1.2% | 1.3% | 7% (–14 to 24) | Not significant |
| Death at 30 days | 3.4% | 3.7% | 9% (–3 to 18) | Not significant |
| CABG or PCI at 5 days | 18% | 20% | 4% (–1 to 8) | Not significant |
| CABG or PCI at 30 days | 38% | 39% | 1% (–2 to 4) | Not significant |
| Death or MI at 30 days Men only | 10% | 13% | 17% (10 to 23) | 47 (36 to 82) |
| RRI (CI) | NNH (CI) | |||
|---|---|---|---|---|
| *CABG = coronary artery bypass grafting; MI = myocardial infarction; PCI = percutaneous coronary intervention. Other abbreviations defined in glossary; RRR, RRI, NNT, NNH, and CI calculated from data in article. | ||||
| Women only | 12% | 10% | 13% (1 to 26) | 73 (37 to 1072) |
| Major bleeding at 30 days | 2.4% | 1.4% | 61% (35 to 92) | 121 (80 to 207) |